Overview of PET/CT Imaging in Recurrent Prostate Cancer – Current and Emerging Techniques

From Dr. Fabio’s blog post:

Over the last few years, we have seen tremendous activity in the area of molecular imaging for prostate cancer. Just about every day we have colleagues asking about the various PET/CT imaging tests – what is available?  How do they compare?  What are the parameters for successful imaging?

We are proud to have contributed to this body of knowledge. Our work regarding C11-Acetate PET/CT imaging in the recurrent PCa setting with relationship to PSA kinetics has been recently published – representing the largest single-site evaluation of a molecular imaging agent. A link to the publication and brief overview of PET/CT Imaging for Prostate Cancer follow for your review.  We hope you find this review useful.

Read the entire article on drfabio.com HERE

Prostate cancer–specific PET radiotracers: A review on the clinical utility in recurrent disease

Prostate cancer–specific positron emission tomography (pcPET) has been shown to detect sites of disease recurrence at serum prostate-specific antigen (PSA) levels that are lower than those levels detected by conventional imaging. Commonly used pcPET radiotracers in the setting of biochemical recurrence are reviewed including carbon 11/fludeoxyglucose 18 (F-18) choline, gallium 68/F-18 prostate-specific membrane antigen (PSMA), and F-18 fluciclovine.

Note that this article mentions C-11 acetate briefly but does not cover it. Phoenix Molecular Imaging is not shown on the map of imaging centers.  Also, the study does not examine the significance of PSA doubling time, whereas it has been reported that short doubling time enhances detection with C11-Acetate even at very low PSA.

Read the entire article on sciencedirect.com HERE

US Too Prostate Cancer Panel Discussion and Webcast on Advanced Prostate Cancer

US Too Prostate Cancer Panel Discussion and Webcast on Advanced Prostate Cancer

  • Presented by: Bayer
  • Sponsored by: Dendreon and Jannsen Oncology
  • In Kind Sponsor: Los Padres
  • Guest Speakers:
    • Dr. Edwin Morales – Urology Specialist, San Antonio
    • Dr. Michael Liss – Urologist, Urologic Oncologist, and Lead Prostate Cancer Researcher at UT Health, San Antonio
    • Dr. Vijay K. Gunuganti – Medical Oncologist at Texas Oncology
    • Moderator: Dr. Juan A. Reyna – Staff Physician at Audie L. Murphy Memorial VA Hospital; and Clinical Faculty at UT Health

Watch the recording here

Dr. Mark Scholz and Panel Discussion Video – El Camino Hospital

Dr. Mark Scholz participated in a tumor board session with a discussion of Prostate Cancer Cases at El Camino Hospital in November 2017.

Participants included:

  • Robert Sinha, MD, Medical Director of Radiation Oncology
  • Frank Lai, MD, Urological Oncologist/Robotic Surgeon, El Camino Hospital
  • Steven Kurtzman, MD, Radiation Oncologist, Director of Prostate Brachytherapy, El Camino Hospital
  • Shane Dormady, MD PhD, Medical Director of Oncology, El Camino Hospital
  • Mark Scholz, MD, Medical Oncology, Director of Prostate Cancer Specialists, Founder of Prostate Cancer Research Institute

View the recording of the event here

A Short Course in Prostate Cancer by Thomas J. Leih (eBook)

A Short Course in Prostate Cancer – eBook

The purpose of this short eBook is to provide men facing prostate cancer with a lot of up-to-date information in a compact format.

The information and opinions provided in this book are not specific medical advice for any individual. It  should not substitute for medical advice from a healthcare professional. The author is not a medical doctor. The reader is advised that any information or opinions expressed or implied in this book are those of a layman and should not be acted upon without the consent of a licensed physician. This book is not meant to be used, nor should it be used, to diagnose or treat any medical condition. For diagnosis or treatment of any medical problem, consult your own physician.

Download the pdf ebook here.

Overview of PET/CT Imaging in Recurrent Prostate Cancer – Current and Emerging Techniques

Fabio Almeida, MD // Phoenix Molecular Imaging – Phoenix Insight Imaging/CDI

Over the last few years, we have seen tremendous activity in the area of molecular imaging for prostate cancer. Just about every day we have colleagues asking about the various PET/CT imaging tests – what is available? How do they compare? What are the parameters for successful imaging?

We are proud to be contributing to this body of knowledge. Our work regarding C11-Acetate PET/CT imaging in the recurrent PCa setting with relationship to PSA kinetics has been recently published. This represents the largest single-site evaluation of a molecular imaging agent. A link to the publication and brief overview PET/CT imaging for Prostate Cancer follow for your review. We hope you find this information useful.

Read or download the report from here